Clinical Trial Update: A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients [Phase 1]

View source ↗

Summary

Update on a two-arm, single-center Phase 1b trial evaluating Bavituximab plus Ipilimumab in advanced melanoma, which has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Bavituximab (bavituximab)
• ipilimumab (ipilimumab)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Melanoma | Phase 1 | Status: TERMINATED